BVS - Bioventus Total Debt to Capital

Bioventus Corp (BVS) - corporate logo

A strong team of healing experts and a sophisticated sales system support the human capital potential of Bioventus Inc. (BVS). The total debt-to-equity ratio demonstrates the current debt load, where 1.09 characterizes this valuation parameter. Stable demand for mature orthopedic solutions, combined with the expansion strategy of Exogen systems in US clinics, ensures margin protection and growth in business value.

BVS: bioventus.com Total Debt to Equity Ratio 07/04/2022 - 10/30/2026
Finished products of Bioventus Inc.

For Bioventus Inc. (BVS), this indicator serves as a measure of financial stability during a period of business transformation. The ratio of total liabilities to equity on the debt-to-equity chart determines the share of borrowed financing within the balance sheet structure. An increase in this metric signals insolvency risks, while a decrease indicates deleveraging. Amid restructuring and asset sales, this figure reflects the efficiency of reducing the debt load. It is critical for investors to track the downward trend of this ratio to confirm the success of the model pivot.

Competitor analysis

Debt to Equity Boston Scientific Corporation|Edwards - Aggregate Debt to Equity|Total Debt to Capital RMD|PODD - Debt to Capital|Total Debt to Capital ZBH (Zimmer Biomet Corp)|COO - Total Debt to Equity Ratio|Align Technology - Total Debt to Capital|Total Debt to Capital Coefficient Globus Medical Inc GMED|TMDX: Total Debt to Capital|Alphatec Corp (ATEC) - Total Debt to Capital|Debt to Equity Artivion, Inc.|Debt to Equity ENOV|Total Debt to Capital IART|Total Debt to Capital Coefficient Establishment Labs Corp|Beta Bionics Corp - Total Debt to Equity Ratio|IRMD (IRADIMED Inc.) - Aggregate Debt to Equity|Embecta Corp. - Total Debt to Capital|Debt to Capital tandemdiabetes.com|AXGN: Total Debt to Capital|Debt to Equity Ratio SIBN|Total Debt to Equity Ratio OFIX|KIDS: All Debt to Shareholders' Equity Ratio|Debt to Equity Treace Medical Concepts (TMCI)|Total Debt to Equity Ratio blade.com SRTA|Total Debt to Capital CARL (Carlsmed)|RxSight Inc (RXST) - Debt to Capital|ClearPoint - Total Debt to Capital|STXS (Stereotaxis Corporation) - Debt to Equity Ratio|STIM: Total Debt to Capital|SGHT - Total Debt to Capital Coefficient|OBIO (Orchestra BioMed, Inc.) - Total Debt to Capital|Total Debt to Equity Ratio Anika (ANIK)|Total Debt to Capital NSPR|Total Debt to Capital zhjmedical.com (ZJYL)|Debt to Equity Vivani Medical VANI|Xtant Medical Holdings, Inc. - Debt to Equity|NMTC: Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio MODD (Modular Medical)|MYO: Total Debt to Capital|Debt to Capital Envoy Medical Inc (COCH)|Debt to Equity Vivos Therapeutics|NVNO - Debt to Capital Ratio|Total Debt to Equity Ratio SINT (Sintx Technologies)|Total Debt to Capital Tenon Medical Inc. (TNON)|Total Debt to Capital LFWD (ReWalk Robotics Ltd)|Total Debt to Capital Coefficient Autonomix Medical Inc. (AMIX)|IVF - Debt to Equity|Aggregate Debt to Equity BBLG|Axonics (AXNX) - Debt to Equity|Total Debt to Equity Ratio BIOLASE Inc.|DYNT (Dynatronics Corp) - Total Debt to Capital|Debt to Capital Paragon 28 Corp FNA|Debt to Equity INVO Bioscience, Inc. (INVO)